116 related articles for article (PubMed ID: 18008332)
1. Involvement of decreased Galectin-3 expression in the pathogenesis and progression of prostate cancer.
Merseburger AS; Kramer MW; Hennenlotter J; Simon P; Knapp J; Hartmann JT; Stenzl A; Serth J; Kuczyk MA
Prostate; 2008 Jan; 68(1):72-7. PubMed ID: 18008332
[TBL] [Abstract][Full Text] [Related]
2. Activation of the PKB/Akt pathway in histological benign prostatic tissue adjacent to the primary malignant lesions.
Merseburger AS; Hennenlotter J; Simon P; Müller CC; Kühs U; Knüchel-Clarke R; Moul JW; Stenzl A; Kuczyk MA
Oncol Rep; 2006 Jul; 16(1):79-83. PubMed ID: 16786126
[TBL] [Abstract][Full Text] [Related]
3. Expression and nuclear localization of ErbB3 in prostate cancer.
Koumakpayi IH; Diallo JS; Le Page C; Lessard L; Gleave M; Bégin LR; Mes-Masson AM; Saad F
Clin Cancer Res; 2006 May; 12(9):2730-7. PubMed ID: 16675564
[TBL] [Abstract][Full Text] [Related]
4. Decreased expression of galectin-3 predicts tumour recurrence in pTa bladder cancer.
Kramer MW; Kuczyk MA; Hennenlotter J; Serth J; Schilling D; Stenzl A; Merseburger AS
Oncol Rep; 2008 Dec; 20(6):1403-8. PubMed ID: 19020721
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical localization of human kallikreins 6, 10 and 13 in benign and malignant prostatic tissues.
Petraki CD; Gregorakis AK; Papanastasiou PA; Karavana VN; Luo LY; Diamandis EP
Prostate Cancer Prostatic Dis; 2003; 6(3):223-7. PubMed ID: 12970725
[TBL] [Abstract][Full Text] [Related]
6. Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy.
Rosner IL; Ravindranath L; Furusato B; Chen Y; Gao C; Cullen J; Sesterhenn IA; McLeod DG; Srivastava S; Petrovics G
Urology; 2007 Dec; 70(6):1225-9. PubMed ID: 18158066
[TBL] [Abstract][Full Text] [Related]
7. Loss of the matriptase inhibitor HAI-2 during prostate cancer progression.
Bergum C; List K
Prostate; 2010 Sep; 70(13):1422-8. PubMed ID: 20687215
[TBL] [Abstract][Full Text] [Related]
8. [Expression of galectin 3 and Sambucus nigra agglutinin and their clinicopathological significance in benign and malignant lesions of stomach].
Zhou JP; Yang ZL; Liu DC; Zhou JP
Zhonghua Wei Chang Wai Ke Za Zhi; 2009 May; 12(3):297-300. PubMed ID: 19434543
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of galectins in normal, benign and malignant prostate epithelial cells: silencing of galectin-3 expression in prostate cancer by its promoter methylation.
Ahmed H; Banerjee PP; Vasta GR
Biochem Biophys Res Commun; 2007 Jun; 358(1):241-6. PubMed ID: 17481580
[TBL] [Abstract][Full Text] [Related]
10. IL-6, IL-10 and HSP-90 expression in tissue microarrays from human prostate cancer assessed by computer-assisted image analysis.
Cardillo MR; Ippoliti F
Anticancer Res; 2006; 26(5A):3409-16. PubMed ID: 17094460
[TBL] [Abstract][Full Text] [Related]
11. Aberrant expression of cystatin C in prostate cancer is associated with neuroendocrine differentiation.
Jiborn T; Abrahamson M; Gadaleanu V; Lundwall A; Bjartell A
BJU Int; 2006 Jul; 98(1):189-96. PubMed ID: 16831167
[TBL] [Abstract][Full Text] [Related]
12. A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease.
Laderach DJ; Gentilini LD; Giribaldi L; Delgado VC; Nugnes L; Croci DO; Al Nakouzi N; Sacca P; Casas G; Mazza O; Shipp MA; Vazquez E; Chauchereau A; Kutok JL; Rodig SJ; Elola MT; Compagno D; Rabinovich GA
Cancer Res; 2013 Jan; 73(1):86-96. PubMed ID: 23108139
[TBL] [Abstract][Full Text] [Related]
13. BCAR1 expression in prostate cancer: association with 16q23 LOH status, tumor progression and EGFR/KAI1 staining.
Fromont G; Vallancien G; Validire P; Levillain P; Cussenot O
Prostate; 2007 Feb; 67(3):268-73. PubMed ID: 17192874
[TBL] [Abstract][Full Text] [Related]
14. Group IIA phospholipase A as a prognostic marker in prostate cancer: relevance to clinicopathological variables and disease-specific mortality.
Mirtti T; Laine VJ; Hiekkanen H; Hurme S; Rowe O; Nevalainen TJ; Kallajoki M; Alanen K
APMIS; 2009 Mar; 117(3):151-61. PubMed ID: 19245588
[TBL] [Abstract][Full Text] [Related]
15. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
[TBL] [Abstract][Full Text] [Related]
16. CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer.
Zhong WD; Han ZD; He HC; Bi XC; Dai QS; Zhu G; Ye YK; Liang YX; Qin WJ; Zhang Z; Zeng GH; Chen ZN
Oncology; 2008; 75(3-4):230-6. PubMed ID: 18852494
[TBL] [Abstract][Full Text] [Related]
17. The involvement of altered corticotropin releasing factor receptor 2 expression in prostate cancer due to alteration of anti-angiogenic signaling pathways.
Tezval H; Jurk S; Atschekzei F; Serth J; Kuczyk MA; Merseburger AS
Prostate; 2009 Mar; 69(4):443-8. PubMed ID: 19058138
[TBL] [Abstract][Full Text] [Related]
18. The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer.
Edwards J; Traynor P; Munro AF; Pirret CF; Dunne B; Bartlett JM
Clin Cancer Res; 2006 Jan; 12(1):123-30. PubMed ID: 16397033
[TBL] [Abstract][Full Text] [Related]
19. Fascin regulates prostate cancer cell invasion and is associated with metastasis and biochemical failure in prostate cancer.
Darnel AD; Behmoaram E; Vollmer RT; Corcos J; Bijian K; Sircar K; Su J; Jiao J; Alaoui-Jamali MA; Bismar TA
Clin Cancer Res; 2009 Feb; 15(4):1376-83. PubMed ID: 19228738
[TBL] [Abstract][Full Text] [Related]
20. Comparative expression of Hedgehog ligands at different stages of prostate carcinoma progression.
Azoulay S; Terry S; Chimingqi M; Sirab N; Faucon H; Gil Diez de Medina S; Moutereau S; Maillé P; Soyeux P; Abbou C; Salomon L; Vacherot F; de La Taille A; Loric S; Allory Y
J Pathol; 2008 Dec; 216(4):460-70. PubMed ID: 18825689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
